Want to see MIRM full AI Analyst Report?
MIRM Stock Chart & Stats
$113.03
-$1.33(-1.16%)
At close: 4:00 PM EDT
$113.03
-$1.33(-1.16%)
Day’s Range― - ―
52-Week Range$63.23 - $130.00
Previous CloseN/A
Volume516.94K
Average Volume (3M)919.61K
Market Cap
$6.30B
Enterprise Value$7.74K
Total Cash (Recent Filing)$438.29M
Total Debt (Recent Filing)$760.54M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Nov 17, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.56
Shares Outstanding64,932,205
10 Day Avg. Volume584,111
30 Day Avg. Volume919,612
Financial Highlights & Ratios
PEG Ratio2.25
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$135.10Price Target Upside19.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-15.13
Revenue Forecast (FY)$697.93M
Bulls Say, Bears Say
Bulls Say
Strong Product Revenue Growth And Raised GuidanceRapid portfolio-led growth and higher full-year guidance indicate durable demand for LIVMARLI and bile-acid medicines. Continued diagnosis, reimbursement expansion and specialty distribution could support sustained revenue growth over the next several quarters.
Healthy And Improving Commercial EconomicsStrong gross profitability and improving commercial contribution suggest Mirum can retain meaningful economics as sales scale. Better margins provide greater capacity to fund development, absorb commercial investment and move toward sustainable profitability.
Diversified Pipeline With Multiple Regulatory And Clinical OpportunitiesSeveral programs across rare liver diseases and other indications reduce reliance on a single product and create multiple routes to future growth. Regulatory filings and clinical readouts over the coming quarters could expand Mirum’s addressable markets.
Bears Say
Severe Profitability DeteriorationThe sharp earnings deterioration shows that strong sales have not yet translated into dependable bottom-line performance. Persistent operating drag, development spending and noncash charges could delay the company’s path to durable profitability.
Cash Burn And Weakened Capital StructureNegative cash generation and negative shareholders’ equity reduce financial flexibility despite sizable assets and reported cash. Higher leverage may increase dependence on financing, constrain investment choices and heighten dilution or refinancing risk.
FDA-requested Phase 3 Delays The PSC OpportunityThe requested additional trial creates regulatory execution risk and pushes potential PSC commercialization beyond prior expectations. It may require more capital and prolong uncertainty around the timing and probability of revenue from this indication.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $63.23 and its highest was $130.00 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Mirum Pharmaceuticals Inc’s market cap is $6.30B.
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Nov 17, 2026 which is in 87 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Aug 05, 2026. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$0.743 by -$0.317.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -0.53.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 64,932,205 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$1.06 in its last earnings report, missing expectations of -$0.743. Following the earnings report the stock price went down -11.036%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$135.10 (19.53% Upside)
$135.10 (19.53% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 80%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 172.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.97%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
MIRM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial execution (Q2 sales up 37.5% YoY), improved margins (+~5 percentage points) a fortified balance sheet (cash up ~43.5%, successful convertible note financing), and multiple near-term clinical and regulatory catalysts (Zilurgisertib PDUFA, volovitug/volixibat and volovitug AZURE readouts). The most significant negative item is regulatory uncertainty for volixibat in PSC after the FDA recommended a Phase 3, leading to an NDA timing delay to H1 2027 and added execution risk. Overall, positive commercial and financial momentum and multiple upcoming catalysts outweigh the regulatory setback, but the PSC pathway remains a material watch item.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$135.10
▲(19.53% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
PTC Therapeutics
―
Viking Therapeutics
―
Ownership Overview
7.48% Insiders
28.08% Mutual Funds
45.72% Other Institutional Investors
4.60% Public Companies and
Individual Investors